Inherited lung diseases, such as cystic fibrosis (CF) and alpha-1 antitrypsin deficiency and acquired lung diseases, such as lung cancer, are attractive conditions for gene therapy. 1 However, one of the challenges of gene therapy for pulmonary diseases is determining the successful expression of the transgene in the airway epithelia in vivo. Methods commonly employed to demonstrate successful expression of transgene include, detection of transgene DNA by polymerase chain reaction (PCR), the use of reverse transcription PCR (RT-PCR) from the transgene mRNA, in situ hybridization and immunocytochemistry. All of these techniques require a sample of the transfected tissue, such as a biopsy or brushing sample. 2 However, brushing or biopsy may affect the expression or longevity of the expressed transgene in vivo. In CF, non-invasive methods of detecting successful expression of the CFTR transgene have been used, these include measuring the correction in transepithelial voltage in CF patients by nasal voltage measurements [3] [4] [5] or in large airways. 6 This technique is difficult to perform and can be affected by other ongoing inflammatory activity in the epithelial surface measured. 7, 8 In lung cancer, mutation of the p53 tumor suppressor gene is one of the most common genetic abnormalities in non-small cell carcinoma. Introduction of the wild-type p53 into tumors of patients with non-small cell carcinoma expressing the nonfunctional p53 mutation, is associated with tumor regression. 9, 10 In gene therapy trials where lung cancer patients have the p53 gene reintroduced into the tumor, the marker of success of gene transfer is made by clinical, radiological and endoscopic regression in tumor. [9] [10] [11] This clinical method of measurement of gene transfer does not tell us if gene transfer in itself is efficient or not, as a lack of clinical response may not necessarily mean poor gene transfer in the target tissue.
As a method to determine successful expression of the transgene in vitro, the use of reporter genes or marker genes have been included in the vector. Green fluorescent protein (GFP) is used as a reporter gene, and GFP cDNA encodes for a 238 amino acid chromophore that produces strong green fluorescence when excited by blue light. It requires no exogenous substrates or co-factors for activity, thus cells expressing GFP can be easily scored by FACS scan or fluorescent microscopy. [12] [13] [14] [15] A fluorescence video endoscope has been shown to detect GFP in rabbit airways. 16 This technique was found to be not very sensitive on human airway epithelia, because of the relatively low light emission. Laserinduced fluorescence bronchoscopy is used to detect precancerous lesions and early stage lung cancer due to differences in autofluorescence between cancerous and noncancerous tissue. 17 Positron emission tomography (PET) has been demonstrated to be a useful method of detecting gene transfer in animal models. Yu et al 18 successfully detected gene transfer in mice using a bi-cistronic construct containing a PET reporter gene, eg herpes simplex virus type-1 thymidine kinase and a PET reporter probe such as 8-[
18 F] fluorogangciclovir. The charged coupled device (CCD) camera has been used as a non-invasive tool to detect the expression of the reporter gene firefly luciferase in a mouse model. 19 We wished to evaluate the efficacy of laser-induced fluorescence bronchoscopy used in combination with a CCD camera system as a method of detecting airway epithelia that have been successfully infected with a recombinant adenoviral type 5 containing a gene for GFP. Our hypothesis is that successful detection of GFP expression by laser bronchoscopy would obviate need for obtaining a sample target tissue, thereby enhancing longevity of the transgene and reducing need of biopsies or brush samples to be obtained from the patient. Many pulmonary gene therapy trials use the bronchoscope as a method to administer vector. In the case of the lung cancer trials, the bronchoscopic examination of the lesion in question is used not only to deliver vector, but also as a method to determine response of the tumor to treatment. If this model were successful, it would allow determination of the relative success in transfecting the airway epithelia without needing biopsy material. It would also facilitate assessment of extent or area of tissue transfected and if repeated administration is required, longevity of transgene expression in the target tissue.
The laser bronchoscopy system, as described below in Figure 1 , consists of an argon ion laser that can deliver a narrow beam of blue light (488 nm) down a fiber optic cable via the working channel of a standard bronchoscope. This beam of laser light can excite the expressed GFP and the resultant green fluorescence is detected by a CCD camera that has been fitted with a filter to allow only green light through, thus recording the green fluorescence elicited, which will be expressed as CCD pixels. The data from these images are then fed into a computer software system, Digital Optics V++ Precision Digital Imaging System version 4 software, which can recreate a three-dimensional digital reconstruction of the airway in 12-bit digital images (1024 × 1024 pixels on the x and y axis, respectively). These digital reconstructions of the airways demonstrate the calculated fluorescence intensity in the z-axis, giving a semi-quantitative measurement of the fluorescence present.
To ensure that the laser fluorescence bronchoscopy system could detect GFP expressed in airway epithelia cells, we initially transfected primary human airway epithelial culture with Ad5-GFP in increasing multiplicity of infection (MOI) and examined the epithelia 2 days after infection with the laser fluorescence bronchoscopic system (Figure 2a) . GFP expression could be visualized by laser fluorescence bronchoscopy at the higher MOI of Ad5-GFP. To correlate the degree of fluorescent light visualized by the bronchoscopic method to GFP expressed in the airway epithelia cells, the airway epithelia were trypsinized following examination by laser bronchoscope, and their GFP expression confirmed by FACS analysis (Figure 2b ). This suggests that laser bronchoscopy can detect GFP expression in airway epithelia.
Following successful demonstration that this laser fluorescence bronchoscopic system can excite and detect GFP expressed in primary airway epithelia culture in vitro, we then went on to examine this system in an tracheal model. New Zealand White rabbits were killed and the tracheas excised. It is well recognized that airway epithelia cells express the receptor for adenovirus, the coxsackie-adenovirus receptor (CAR) on the basolateral surface and is not available to bind to adenovirus applied to the apical surface. 20, 21 To enhance adenoviral access to Figure 2 Primary cultures of normal human airway epithelia were isolated and grown as described previously. 27 the basolateral CAR, the airway epithelia of the endotracheal surface was abraded, as this enhances gene transfer. 22 A circular pattern was used to allow easier identification. Increasing infectious units of Ad5/GFP were then applied to the abraded endotracheal surface for 1 h and then washed off and the tracheal tissue resuspended in fresh medium. GFP expression was evaluated 24 h later by the laser bronchoscopic system. Figure 3a demonstrates the typical circular fluorescence pattern seen, reflecting the GFP expressed in the circular abraded areas on the endotracheal surface (1 × 10 7 infectious units of Ad5/GFP applied to this area). A reconstructed digital image of the same area is presented in Figure 3b . It can be seen that fluorescence intensity expressed on the z axis mirrors the image visualized in Figure 3a . Figure 3c demonstrates that increasing infectious units is associated with increasing numbers of pixels of fluorescent light detected. Even though lower doses of infectious units (10 4 - 10 5 ) allowed for fluorescent light detection by the CCD camera, it was noted that adequate visualization of GFP by eye was achieved when infectious units of 10 6 -10 7 were used. Having established that GFP detection could be achieved in mammalian trachea in vitro, we next examined the use of this bronchoscopic system in vivo. Two male adult Rhesus monkeys initially underwent a bronchoscopic examination under 'white light' (Figure 4a right bronchus, Figure 4b left bronchus), which was followed by a re-examination with the laser light source to evaluate for any degree of mucosal autofluorescence that may be elicited (Figure 4c right bronchus, Figure 4d left bronchus). Once it was confirmed that the laser system did not induce autofluorescence of respiratory epithelia in vivo, the junction of the right upper lobe and right main stem was abraded with a cytology brush. Similarly, the junction of the left upper lobe and left main stem was also abraded. 1 ml of 10 12 particles of Ad5-GFP was slowly dripped on to the abraded area on the right side, with vehicle alone applied to the abraded area on the left. These animals were examined for fluorescence on day 3 and day 8 after application and then twice weekly for 8 weeks. The right upper lobe bronchus demonstrated green fluorescence by day 3 (Figure 4e ) and day 8 ( Figure  4g ), whereas the left upper lobe bronchus did not demonstrate an increase in fluorescence secondary to either viral 'spill-over' or secondary to abrasion of the surface epithelia on either days 3 or 8 (Figure 4f and h) . In one animal, the fluorescent tissue was biopsied and examined by fluorescence microscopy, to confirm GFP expression in the airway epithelia ( Figure 5 ). Florescence appeared to be maximal between day 10 and 14 and decline slowly thereafter, with no expression noted at 8 weeks. The animal which received the biopsy demonstrated a more rapid loss of fluorescence.
This technique demonstrates a bronchoscopic method, which can visualize GFP transgene expression in the air- Applications of this technique in longitudinal pre-clinical studies evaluating efficacy and duration of expression in large animals would significantly reduce the number of animals and vector required, thereby reducing costs. In clinical studies such as lung cancer gene therapy, the introduction of the wild-type p53 into tumors of patients with non-small cell carcinoma expressing the nonfunctional p53 mutation, could be measured by using a GFPp53 fusion chimera 23 in combination with the fluorescence bronchoscopic system, thus allowing endoscopic detection of transgene expression without the need for tissue. In esophageal carcinoma, a similar p53 deletion has been detected and a similar approach to restoring wild-type p53 with gene therapy to these tumors as adjunctive cancer therapy has been proposed. 24 However, application of the vector in the lung cancer p53 gene therapy trials are by injection and surface expression of a reporter protein may not be seen. Thus, other application methods including surface application of vector to the tumor may need to be used to avail of a laser fluorescence bronchoscopy system to detect the reporter protein GFP. Similarly, a cystic fibrosis transmembrane conductance regulator (CFTR) has been fused with GFP and used as Gene Therapy a marker for successful transgene expression. 25 Similar constructs could be used in vivo for clinical CF gene therapy studies. The laser fluorescence bronchoscopy system described here would have applications for detection of transgene in other surface epithelial sites accessible by endoscopy, such as gastrointestinal, genitourinary and peritoneal epithelial surfaces.
There are some disadvantages with this system. The level of expression of this reporter gene per cell is likely to be higher than that of the transgene of interest. 26 Second, the subject would need to undergo frequent bronchoscopies, but in many of the clinical studies listed above, bronchoscopy is the method of vector delivery and the method of retrieval of samples to detect expression of transgene.
In summary, we have developed a laser fluorescence bronchoscope system that can detect the reporter gene, GFP, in a semi-quantitative fashion in vivo in the airways of monkeys following adenoviral transfection, without the need for target tissue samples. This system will have many relevant applications in pre-clinical and clinical gene therapy to surface epithelia accessible by endoscopy.
